218 related articles for article (PubMed ID: 33606571)
1. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden.
George G; Vikman H; Gedeborg R; Lissbrant IF; Garmo H; Styrke J; Van Hemelrijck M; Stattin P
Acta Oncol; 2021 Apr; 60(4):459-465. PubMed ID: 33606571
[TBL] [Abstract][Full Text] [Related]
2. Long-term adherence to GnRH agonists in men with prostate cancer. A nation-wide population-based study in prostate cancer data base Sweden.
George G; Garmo H; Rudman S; Holmberg L; Robinson D; Stattin P; Adolfsson J; Van Hemelrijck M
Scand J Urol; 2020 Feb; 54(1):20-26. PubMed ID: 31842658
[No Abstract] [Full Text] [Related]
3. Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based Study.
Thomsen FB; Sandin F; Garmo H; Lissbrant IF; Ahlgren G; Van Hemelrijck M; Adolfsson J; Robinson D; Stattin P
Eur Urol; 2017 Dec; 72(6):920-928. PubMed ID: 28711383
[TBL] [Abstract][Full Text] [Related]
4. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
5. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden.
Fallara G; Alverbratt C; Garmo H; Vikman H; Hjelm Eriksson M; Lissbrant IF; Stattin P
Acta Oncol; 2021 Dec; 60(12):1589-1596. PubMed ID: 34533422
[TBL] [Abstract][Full Text] [Related]
6. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes.
Lin E; Garmo H; Van Hemelrijck M; Zethelius B; Stattin P; Hagström E; Adolfsson J; Crawley D
JAMA Netw Open; 2022 Aug; 5(8):e2225600. PubMed ID: 35939302
[TBL] [Abstract][Full Text] [Related]
7. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer.
O'Farrell S; Garmo H; Holmberg L; Adolfsson J; Stattin P; Van Hemelrijck M
J Clin Oncol; 2015 Apr; 33(11):1243-51. PubMed ID: 25732167
[TBL] [Abstract][Full Text] [Related]
8. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
9. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: Real-world evidence from five databases.
George G; Garmo H; Scailteux LM; Balusson F; De Coster G; De Schutter H; Kuiper JG; Oger E; Verbeeck J; Van Hemelrijck M
Int J Cancer; 2021 May; 148(9):2203-2211. PubMed ID: 33186481
[TBL] [Abstract][Full Text] [Related]
10. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
Lai LY; Oerline MK; Caram MEV; Tsao PA; Kaufman SR; Hollenbeck BK; Shahinian VB
J Natl Cancer Inst; 2022 Aug; 114(8):1127-1134. PubMed ID: 35417024
[TBL] [Abstract][Full Text] [Related]
11. Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients.
Kulkarni AA; Rubin N; Tholkes A; Shah S; Ryan CJ; Lutsey PL; Prizment A; Rao A
ESMO Open; 2021 Oct; 6(5):100261. PubMed ID: 34509804
[TBL] [Abstract][Full Text] [Related]
12. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer: a register-based, observational study.
Thomsen FB; Bosco C; Garmo H; Adolfsson J; Hammar N; Stattin P; Van Hemelrijck M
Acta Oncol; 2019 Jan; 58(1):110-118. PubMed ID: 30375907
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
14. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
16. Observational study on time on treatment with abiraterone and enzalutamide.
Fallara G; Lissbrant IF; Styrke J; Montorsi F; Garmo H; Stattin P
PLoS One; 2020; 15(12):e0244462. PubMed ID: 33370378
[TBL] [Abstract][Full Text] [Related]
17. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
Pezaro CJ; Omlin AG; Altavilla A; Lorente D; Ferraldeschi R; Bianchini D; Dearnaley D; Parker C; de Bono JS; Attard G
Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
[TBL] [Abstract][Full Text] [Related]
18. Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study.
Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
BMC Cancer; 2021 Nov; 21(1):1259. PubMed ID: 34809595
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular events among patients with prostate cancer treated with abiraterone and enzalutamide.
Baser O; Samayoa G; Dwivedi A; AlSaleh S; Cigdem B; Kizilkaya E
Acta Oncol; 2024 Apr; 63():137-146. PubMed ID: 38591349
[TBL] [Abstract][Full Text] [Related]
20. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
Lee HY; Chen HL; Teoh JY; Chen TC; Hao SY; Tsai HY; Huang WH; Juan YS; Cheng HM; Chang HM
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):244-252. PubMed ID: 32860011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
